Theriva Biologics Inc (TOVX) Stock Price, Quote & News

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorect...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

HectorNumba9 Oct. 4 at 6:56 PM

$TOVX Less we this data blows the world which we can. Its 2026 no rs thank god. If data is good but not pump worthy its small bo. I think there's more bigger news. U cant be angry. Tho im sure he couldnt rs for millionth time W is a W for progress

0 · Reply

ZACHSPIZZA Oct. 3 at 2:23 PM

$TOVX and yet it’s still .39

1 · Reply

HectorNumba9 Oct. 3 at 1:38 PM

$TOVX Told u. Super Bullish⏳

0 · Reply

HouseOfTheDragons Oct. 3 at 2:53 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $SOAR $TOVX $HYZN $SMX bullish

1 · Reply

Thess5 Oct. 2 at 11:16 PM

$TOVX Saw the million plus after hours.🧐. One of my watches since 2020! Might be getting in premarket tomorrow $ABKB $NEON $BOXL $DAIC 🧐

0 · Reply

exwallstcfo Oct. 2 at 9:51 PM

$TOVX Theriva Biologics Cuts 32% Of Workforce In Restructuring To Focus On Cancer Drug Development And Regulatory Strategy; Expects Will Extend Its Cash Runway Into Q2 Of 2026 sounds like a plan

1 · Reply

BULLETSTOCK Oct. 2 at 8:55 PM

$TOVX $$$$$$$$$$$$$$$$$$$ $DFLI $$$$$$$$$$$

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:40 PM

$TOVX In any case this is one of those stocks that can very easily 10x even in one day. So if you are investing in biotechs I don't think you can afford to miss this one. Just be sure that you 1. invest only what you can afford to lose and 2. don't sell too early since upside here is huge due to tiny valuation and possibility of good or great phase 2 data coming in few days.

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:35 PM

$TOVX E.g. SP at $3 would only mean 28 million market cap. Even that would be very low for a successful phase 2 pancreatic cancer company having OS HR 0.5 and p value around 0.01-0.03. I think 100 -200 million would be closer to sensible value but I doubt we will get there due to obvious market dynamics with these tiny market cap firms.

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:30 PM

$TOVX The company is going to present updated data at ESMO this month. I think it's going to be very exciting data and p values are going to go down both for PFS and OS. Especially OS is going to be good with p value clearly below 0.05 threshold. Market cap being below 4 million and around 8 million in bank this may explode in coming days.

0 · Reply

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 5 months ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 8, 2025, 4:30 PM EDT - 5 months ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 5 months ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 19, 2025, 8:10 AM EDT - 7 months ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 6, 2025, 4:10 PM EST - 7 months ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 5, 2025, 4:05 PM EST - 7 months ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Dec 5, 2024, 8:00 AM EST - 10 months ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

May 23, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 14, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Apr 25, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

$Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma$

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 22, 2024, 4:35 PM EDT - 1 year ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Mar 25, 2024, 12:01 PM EDT - 1 year ago

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 7:30 AM EDT - 1 year ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Jan 16, 2024, 8:00 AM EST - 1 year ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Nov 17, 2023, 12:51 PM EST - 2 years ago

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 8:00 AM EST - 2 years ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Participate in the Emerging Growth Conference

Aug 12, 2023, 1:52 PM EDT - 2 years ago

Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 1, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Jun 27, 2023, 4:10 PM EDT - 2 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

May 23, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 11, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 4, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 24, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Feb 16, 2023, 12:05 PM EST - 2 years ago

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Jan 17, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

HectorNumba9 Oct. 4 at 6:56 PM

0 · Reply

ZACHSPIZZA Oct. 3 at 2:23 PM

$TOVX and yet it’s still .39

1 · Reply

HectorNumba9 Oct. 3 at 1:38 PM

$TOVX Told u. Super Bullish⏳

0 · Reply

HouseOfTheDragons Oct. 3 at 2:53 AM

1 · Reply

Thess5 Oct. 2 at 11:16 PM

$TOVX Saw the million plus after hours.🧐. One of my watches since 2020! Might be getting in premarket tomorrow $ABKB $NEON $BOXL $DAIC 🧐

0 · Reply

exwallstcfo Oct. 2 at 9:51 PM

$TOVX Theriva Biologics Cuts 32% Of Workforce In Restructuring To Focus On Cancer Drug Development And Regulatory Strategy; Expects Will Extend Its Cash Runway Into Q2 Of 2026 sounds like a plan

1 · Reply

BULLETSTOCK Oct. 2 at 8:55 PM

$TOVX $$$$$$$$$$$$$$$$$$$ $DFLI $$$$$$$$$$$

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:40 PM

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:35 PM

0 · Reply

OnlyTheBestIdeas Oct. 2 at 8:30 PM

0 · Reply

Leopolis Oct. 2 at 8:29 PM

$TOVX this is a preatty clear preparation for buy out news! 🤑

0 · Reply

DaBullRunner Oct. 2 at 8:05 PM

$TOVX there it goes DTCK is going to make a big run soon on that news 🚨 WATCH AND LEARN LIKE HIM👇

0 · Reply

HectorNumba9 Oct. 2 at 1:55 PM

$TOVX News is bout to drop. Its BO or RS

0 · Reply

Nye321 Sep. 30 at 6:53 PM

$TOVX I’m in 10,000 shares let’s go

0 · Reply

bullfish123 Sep. 25 at 5:26 PM

$TOVX ahhh eff it im in. Looks primed

0 · Reply

HectorNumba9 Sep. 25 at 1:35 PM

$TOVX 2.50-$3 buyout⏳

1 · Reply

SPYmyQQQ Sep. 25 at 11:03 AM

🚀 New Signal ✅ 💊 $TOVX 🗓️ Sep 25, 2025 💵 Entry: $0.3942 🎯 Target (Opt.): $0.4672 (+18.52%) 👉 Check bio for full access

0 · Reply

ZACHSPIZZA Sep. 23 at 12:28 PM

$TOVX it’s the same old story here folks except with lower odds of success. Cheap buyout bc the products are very good regardless of the crap management or partnership. Lotto play for that OR you can wait for the dip with possible RS news soon and then play for a quick 25-50% on the bounce into RS.

3 · Reply

paolo73 Sep. 21 at 10:43 AM

$TOVX If nothing happens next week I'll get out....the stock is useless...everything is blocked, insiders have sold all their shares...unfortunately I don't see any alternatives...and since I bought at 0.41 before the price halves because there's no news...it arrives...I'll get out of this disappointment without losses.

0 · Reply

ZACHSPIZZA Sep. 19 at 12:06 PM

$TOVX this has been circling the bowl again on low volume with no interest, but that’s typically the pattern until there is a significant event which I don’t see happening anytime soon but into next year we need to hear how they plan on going about phase 3, which they certainly cannot do on their own, even if they dilute and reverse split again so a partner is needed at this point and a buyout is welcomed, but the CEO is a greedy POS who has done nothing to help investors so I’m betting on partnership.

2 · Reply

HectorNumba9 Sep. 17 at 10:26 AM

$TOVX buyout or death! Maybe not 2025 but oh its coming. Only 1 science ticker i've been wrong really. Has to be a cheap BO. Shallcross crooked self is not taking this commercial! We know this! Phase 3 most likely will be announced with help/partnership if no bo. It will mean nothing! Not 1 patnership in my exp has it ever mattered price wise. It's always 100%-150% max. Thats $1-$1.5 which we wont hold. Less fed surprises us with 50 base point cut. We should hear something by these dates

1 · Reply

HectorNumba9 Sep. 16 at 1:20 PM

$TOVX we know they need cash. Fed cut should give us 50c-60c. It's rs or BO. Nobody that isnt Shallcross's friend is partnering

0 · Reply

Market Cap	3.90M
Revenue (ttm)	0.00
Net Income (ttm)	-25.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	1,072,500
Avg Vol	690,400
Day's Range	N/A - N/A
Shares Out	9.60M
Stochastic %K	71%
Beta	0.65
Analysts	Hold
Price Target	$7.00